Search
Clopenthixol
go.drugbank.com/drugs/DB13841InvestigationalClopenthixol is a thioxanthene with therapeutic actions similar to the phenothiazine antipsychotics. It is an antagonist at D1 and D2 dopamine receptors.
L-tartaric acid
go.drugbank.com/drugs/DB09459ApprovedTartaric acid is a white crystalline organic acid that occurs naturally in many plants, most notably in grapes.Tartaric is an alpha-hydroxy-carboxylic acid, is diprotic and aldaric in acid characteristics … , and is a dihydroxyl derivative of succinic acid.
Synonyms: (+)-L-tartaric acid, L-threaric acidEtravirine
go.drugbank.com/drugs/DB06414ApprovedInvestigationalof rashes in patients taking etravirine, lead to a modification of etravirine's monograph. … Etravirine is an antiretroviral agent more specifically classified as a Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI).
Lymecycline
go.drugbank.com/drugs/DB00256ApprovedInvestigationalWithdrawn[L13880,L13883] It has been proven a cost-effective alternative to treatment with [minocycline] with comparable safety and efficacy.[A203255] Lymecycline was initially discovered in 1961. … It is marketed by Galderma and used in the UK as well as New Zealand in addition to other countries.
Synonyms: Tetracycline-L-methylenelysine, Tetracycline-L-methylene lysineProducts: XELTETRA-LSobuzoxane
go.drugbank.com/drugs/DB21119ExperimentalSobuzoxane is a small molecule drug. The usage of the INN stem '-oxan(e)' in the name indicates that Sobuzoxane is a benzodioxane derivative. … Sobuzoxane has a monoisotopic molecular weight of 514.23 Da.
Categories: Topoisomerase II InhibitorsEthylenediamine
go.drugbank.com/drugs/DB14189ApprovedIt is also used as an excipient in many pharmacological preparations such as creams. Notably, ethylenediamine is a contact sensitizer capable of producing local and generalized reactions [A34285]. … Ethylenediamine is an organic compound that is used as a building block for the production of many other chemical products.
Taletrectinib
go.drugbank.com/drugs/DB18711ApprovedInvestigational[L53308] Gene fusions involving _ROS1_, a proto-oncogene, have been identified as oncogenic drivers in 1-2% of patients with non-small cell lung cancer (NSCLC), in addition to other cancers at variable … [A274118] Taletrectinib was approved by the US FDA in June 2025 for use in patients with advanced ROS1-positive NSCLC.[L53308,L53523]
Faricimab
go.drugbank.com/drugs/DB15303ApprovedInvestigationalefficacy, especially in patients that respond poorly to anti-VEGF-A monotherapy. … [L40026] It received subsequent approval for the same indications in Canada in May 2022.